New Urology Products & Services

Bloomington, IN-Cook Medical has developed the BIGopsy biopsy forceps that capture specimens of sufficient size to produce accurate biopsy results without need for additional samples. The forceps' oversized jaw design and patented backloading handle obtain specimens up to four times larger than those available with traditional forceps, and the 2.4F sheath offers greater flow than do standard 3F sheaths.

Related Videos

Related Content

Advertisement

February 15th 2025

Additional NIAGARA data spotlight benefits of durvalumab plus chemo for MIBC

Benjamin P. Saylor

The pCR was 37.3% (95% CI, 33.2-41.6) in the durvalumab arm and 27.5% (95% CI, 23.8-31.6) in the comparator arm.

February 11th 2025

Episode 3 Podcast: Moving Toward a Patient-Centered Approach in NMIBC Management

Max Kates, MD Neal Shore, MD, FACS Katie S. Murray, DO, MS

Panelists discuss the impact of long-term care in patients with non–muscle-invasive bladder cancer (NMIBC), considering the unique needs of specific patient groups and highlighting advancements in NMIBC treatment that may support better care experiences for patients.

February 14th 2025

Real-world outcomes with nadofaragene point to safety, efficacy of NMIBC treatment

Benjamin P. Saylor

The investigators reported that there were 24 evaluable patients with CIS with/without papillary disease, of whom 79% had a CR at 3 months.

January 29th 2025

Episode 2 Podcast: Identifying Patients with Intermediate Risk in NMIBC

Max Kates, MD Neal Shore, MD, FACS Tom Jayram, MD

Panelists explore challenges in identification of intermediate risk patients and emphasize importance of risk stratification to improve outcomes in regards to NMIBC.

February 14th 2025

Darolutamide plus ADT shows mHSPC benefit regardless of disease volume

Benjamin P. Saylor

"Efficacy outcomes with darolutamide plus ADT were improved vs placebo plus ADT regardless of disease volume," said Fred Saad, MD, FRCS.

February 14th 2025

Radium-223 re-treatment is safe in patients with mCRPC

Benjamin P. Saylor

The median number of re-injections was 6 (range, 1-12).

Related Content

Advertisement

February 15th 2025

Additional NIAGARA data spotlight benefits of durvalumab plus chemo for MIBC

Benjamin P. Saylor

The pCR was 37.3% (95% CI, 33.2-41.6) in the durvalumab arm and 27.5% (95% CI, 23.8-31.6) in the comparator arm.

February 11th 2025

Episode 3 Podcast: Moving Toward a Patient-Centered Approach in NMIBC Management

Max Kates, MD Neal Shore, MD, FACS Katie S. Murray, DO, MS

Panelists discuss the impact of long-term care in patients with non–muscle-invasive bladder cancer (NMIBC), considering the unique needs of specific patient groups and highlighting advancements in NMIBC treatment that may support better care experiences for patients.

February 14th 2025

Real-world outcomes with nadofaragene point to safety, efficacy of NMIBC treatment

Benjamin P. Saylor

The investigators reported that there were 24 evaluable patients with CIS with/without papillary disease, of whom 79% had a CR at 3 months.

January 29th 2025

Episode 2 Podcast: Identifying Patients with Intermediate Risk in NMIBC

Max Kates, MD Neal Shore, MD, FACS Tom Jayram, MD

Panelists explore challenges in identification of intermediate risk patients and emphasize importance of risk stratification to improve outcomes in regards to NMIBC.

February 14th 2025

Darolutamide plus ADT shows mHSPC benefit regardless of disease volume

Benjamin P. Saylor

"Efficacy outcomes with darolutamide plus ADT were improved vs placebo plus ADT regardless of disease volume," said Fred Saad, MD, FRCS.

February 14th 2025

Radium-223 re-treatment is safe in patients with mCRPC

Benjamin P. Saylor

The median number of re-injections was 6 (range, 1-12).